首页> 外文期刊>British Journal of Clinical Pharmacology >A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.
【24h】

A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.

机译:对比较Cypher和Taxus支架治疗阻塞性冠状动脉疾病患者的试验的荟萃分析。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: Drug-eluting stents have been shown to be superior to bare metal stents in reducing restenosis rates. Recently head-to-head trials comparing sirolimus-eluting stents and paclitaxel-eluting stents have been reported. An early combined analysis of these comparative trials is needed. The present meta-analysis was carried out to compare the effects of sirolimus-eluting stents with paclitaxel-eluting stents on the restenosis rate, major adverse cardiac events and late loss of arterial lumen diameter in patients with obstructive coronary artery disease. METHODS: Electronic (Medline, Cochrane and Embase) and manual search (Index Medicus and cross references of retrieved articles) were carried out for all the relevant articles up till March 2005. Only randomized trials with adequate data for calculation of odds ratio for restenosis rates and major adverse cardiac events using the method of DerSimonian & Laird and standardized mean difference for late loss of arterial lumen diameter were included. RESULTS: Four studies were found to be eligible for inclusion in the meta-analysis. Restenosis rate and late loss of arterial lumen diameter were significantly reduced by sirolimus-eluting stents as compared with paclitaxel-eluting stents (OR 0.598, 95% CI 0.400, 0.893, pooled mean difference -0.414, 95% CI -0.492, 0.336, respectively). The incidence of major adverse cardiac events was less with sirolimus-eluting stents as compared with paclitaxel-eluting stents (OR 0.727, 95% CI 0.518-1.018) but the results were not statistically significant. CONCLUSIONS: Sirolimus-eluting stents are superior to paclitaxel-eluting stents in decreasing restenosis rate and late loss of arterial lumen diameter. However, no statistically significant difference in major adverse cardiac events was noted between the two stents.
机译:目的:药物洗脱支架在降低再狭窄率方面优于裸金属支架。最近有头对头试验比较了西罗莫司洗脱支架和紫杉醇洗脱支架。需要对这些比较试验进行早期综合分析。本荟萃分析旨在比较西罗莫司洗脱支架和紫杉醇洗脱支架对阻塞性冠状动脉疾病患者的再狭窄率,主要不良心脏事件和动脉腔直径的晚期损失的影响。方法:直到2005年3月,对所有相关文章进行了电子(Medline,Cochrane和Embase)和手动搜索(Index Medicus和检索到的文献的交叉引用)。只有随机试验中有足够的数据来计算再狭窄率以及使用DerSimonian&Laird方法的主要不良心脏事件以及晚期动脉管腔直径丢失的标准化平均差。结果:发现有四项研究符合纳入荟萃分析的条件。与紫杉醇洗脱支架相比,西罗莫司洗脱支架可显着降低再狭窄率和晚期动脉腔直径损失(OR 0.598、95%CI 0.400、0.893,合并平均差-0.414、95%CI -0.492、0.336 )。与紫杉醇洗脱支架相比,西罗莫司洗脱支架的主要不良心脏事件发生率较低(OR 0.727,95%CI 0.518-1.018),但结果无统计学意义。结论:西罗莫司洗脱支架在降低再狭窄率和动脉腔直径的晚期丢失方面优于紫杉醇洗脱支架。但是,两个支架之间在主要不良心脏事件方面没有统计学上的显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号